#USA #Kidney Care #Deerfield #Vantive #Vital Organ

Vantive: A New Chapter in Kidney Care

Vantive, the newly established vital organ therapy company, emerges from the Baxter Kidney Care segment's renowned 70-year legacy. Officially launched following its acquisition by Carlyle Group, Vantive aims at revolutionizing treatment accessibility and elevating the standards of kidney care. With its headquarters in Deerfield, Illinois, Vantive intends to address the critical needs of the more than four million people undergoing dialysis worldwide.

Vantive’s Mission and Vision

At the core of Vantive’s ethos is the mission to extend lives and expand the possibilities for patients and healthcare providers alike. Vantive recognizes that access to life-saving therapies such as dialysis greatly varies among regions, often resulting in emotional and physical challenges for patients. By equipping patients and care teams with effective and flexible treatment options, Vantive strives to dismantle the barriers to both initiating and adhering to necessary therapies.

Chris Toth, the CEO of Vantive, emphasized the importance of facilitating access to appropriate therapies at critical moments, stating, “This is why our singular focus as Vantive is to empower more patients and care teams in these moments—with better options, greater control, and expanded possibilities.” His statements herald the dawn of a new era in vital organ therapy innovation, reflective of Vantive’s commitment to improving patient outcomes and experiences.

The Vantive Difference

Vantive plans to implement a fully integrated approach, offering innovative products, digital solutions, and advanced services tailored to support dialysis both at home and within clinical settings. Each day, over 1 million interactions occur across more than 100 countries, highlighting the company's extensive impact and influence on patient care.

Among its groundbreaking offerings, Vantive employs remote patient monitoring technology that has shown to reduce the risk of mortality, lower hospitalization rates, and enhance treatment adherence for home dialysis patients.

This innovative infrastructure aims not just to improve the therapy experience for patients but to streamline efficiencies for healthcare providers aiming to deliver optimal care.

Leadership and Strategic Partnerships

Kieran Gallahue, Chairman of the Vantive Board of Directors, mentioned the pivotal role Vantive can play in transforming kidney care. He noted, “With a clear focus on enabling greater connection, visibility, and insights throughout the care journey, Vantive is uniquely positioned to improve the therapy experience for patients and care teams.” This sentiment encapsulates Vantive's forward-thinking approach to patient support within the healthcare landscape.

Along with Carlyle Group's backing, Vantive is poised to expand its global impact, spearheading advancements for long-term success in the healthcare sector. Robert Schmidt, Carlyle's Global Co-Head of Healthcare, conveyed excitement about Vantive’s potential, noting their commitment to enhancing patient care quality and accessibility.

Vantive’s Commitment to Progress

As a vital organ therapy company, Vantive remains steadfast in its dedication to not only elevating the standard of kidney care but also expanding its horizons into broader organ therapies. This commitment is substantiated by the company's focus on digital solutions that aim to deliver more engaging and effective patient experiences.

By prioritizing both flexibility in therapy administration for caregivers and longer, fuller lives for patients, Vantive is on a path to redefine the future of vital organ therapies. To find out more about Vantive and its services, visit Vantive.com or connect through LinkedIn, X, Facebook, Instagram, and YouTube.

Vantive’s launch marks a significant milestone in the evolution of organ therapy, and its initiatives will likely play a crucial role in shaping the future of kidney care.